ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Kane Biotech Inc

Kane Biotech Inc (KNE)

0.13
0.005
(4.00%)
Closed April 29 4:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.13
Bid
0.13
Ask
0.14
Volume
26,200
0.13 Day's Range 0.135
0.05 52 Week Range 0.17
Market Cap
Previous Close
0.125
Open
0.135
Last Trade
22000
@
0.13
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
200,814
Shares Outstanding
124,830,000
Dividend Yield
-
PE Ratio
-4.17
Earnings Per Share (EPS)
-0.03
Revenue
2.67M
Net Profit
-3.89M

About Kane Biotech Inc

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Headquarters
Winnipeg, Manitoba, Can
Founded
1970
Kane Biotech Inc is listed in the Coml Physical, Biologcl Resh sector of the TSX Venture Exchange with ticker KNE. The last closing price for Kane Biotech was $0.13. Over the last year, Kane Biotech shares have traded in a share price range of $ 0.05 to $ 0.17.

Kane Biotech currently has 124,830,000 shares outstanding. The market capitalization of Kane Biotech is $16.23 million. Kane Biotech has a price to earnings ratio (PE ratio) of -4.17.

KNE Latest News

Kane Biotech to Host Investor Webinar

WINNIPEG, Manitoba, April 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday April 18th, 2024 at 4:15pm...

Dual Listed Biotech Firm Achieves Sale of Animal Health Interest, Sending Shares Higher

Shares of this firm hit a 12-month high last week and are seeing action this morning after they announced the completion of the sale of its interest in an animal health unit for USD$8,000,000...

Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products

WINNIPEG, Manitoba, April 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that, it has completed the sale of its interest in STEM Animal Health Inc...

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - KNE

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - KNE Canada NewsWire VANCOUVER, BC, le 11 avril 2024 VANCOUVER, BC, le 11 avril 2024...

Canadian Investment Regulatory Organization Trade Resumption - KNE

Canadian Investment Regulatory Organization Trade Resumption - KNE Canada NewsWire VANCOUVER, BC, April 11, 2024 VANCOUVER, BC, April 11, 2024 /CNW/ - Trading resumes in: Company: Kane Biotech...

Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health

WINNIPEG, Manitoba, April 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has reached an agreement in principle...

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - KNE

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - KNE Canada NewsWire VANCOUVER, BC, le 11 avril 2024 VANCOUVER, BC, le 11 avril 2024...

Canadian Investment Regulatory Organization Trading Halt - KNE

Canadian Investment Regulatory Organization Trading Halt - KNE Canada NewsWire VANCOUVER, BC, April 11, 2024 VANCOUVER, BC, April 11, 2024 /CNW/ - The following issues have been halted by...

Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results

WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023...

Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health

WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.01-7.142857142860.140.1450.125453800.12620097CS
40.02523.80952380950.1050.170.14133780.13338584CS
120.0444.44444444440.090.170.082008140.12367874CS
260.0685.71428571430.070.170.0551188260.11417989CS
520.01513.04347826090.1150.170.05804890.10834337CS
156-0.07-350.20.230.05634960.1202497CS
2600.04552.94117647060.0850.260.05672740.13365898CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CYCCCyclacel Pharmaceuticals Inc
$ 2.37
(74.26%)
930.21k
MRINMarin Software Incorporated
$ 3.42
(31.03%)
1.7M
WGSGeneDx Holdings Corporation
$ 14.23
(29.36%)
24.79k
MULNMullen Automotive Inc
$ 7.10
(24.13%)
5.28M
TTNPTitan Pharmaceuticals Inc
$ 8.40
(22.63%)
186
CACOCaravelle International Group
$ 0.8519
(-13.88%)
256.36k
EKSOEkso Bionics Holdings Inc
$ 1.13
(-12.40%)
12.56k
FFIVF5 Inc
$ 162.50
(-10.78%)
133.97k
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.268
(-10.76%)
210.8k
RAYAErayak Power Solution Group Inc
$ 0.6003
(-10.40%)
2k
CRKNCrown Electrokinetics Corporation
$ 0.0532
(5.35%)
9.1M
MULNMullen Automotive Inc
$ 7.10
(24.13%)
5.28M
AAPLApple Inc
$ 173.56
(0.03%)
3.24M
TSLATesla Inc
$ 193.62
(-0.22%)
2.92M
PARAParamount Global
$ 12.32
(0.57%)
2.89M

KNE Discussion

View Posts
teq0904 teq0904 4 months ago
They have been making about 2,500 samples per month in their lab for distribution to doctors for more than a month. By the time the contract plant starts up at the end of March there will be over 10k samples out so lots of doctors will be familiar with the product. You can bet they went to the burn centers and other of their top identified markets first.
👍️0
teq0904 teq0904 7 months ago
Latest video on kne
https://www.facebook.com/KaneBiotechInc/videos/292568703569665
👍️0
teq0904 teq0904 8 months ago
cc on Tuesday
👍️0
teq0904 teq0904 8 months ago
Doesn't matter what you think the dog market is, because it will be sold. Strategic review nr.
👍️0
teq0904 teq0904 8 months ago
First closing of the financing is probably next week. Officers and directors are in on it.
👍️0
teq0904 teq0904 9 months ago
On the previous cc, Edwards said it is possible that the FDA will approve the manufacturing plant in time for the sales to start in Q4.
👍️0
teq0904 teq0904 9 months ago
The next quarterly cc will be late in August.
👍️0
teq0904 teq0904 9 months ago
The next step is for the outsourced manufacturing of coactiv+ to be completed. It may already be done, but it was supposed to take 3 months after receiving FDA approval.
👍️0
teq0904 teq0904 9 months ago
They have FDA approval for coactiv+.
👍️0
J_Dean J_Dean 3 years ago
This is the year. Let’s go! :)
👍️0
Golden Cross Golden Cross 4 years ago
Kane Biotech Announces Third Quarter 2019
Financial Results

https://backend.otcmarkets.com/otcapi/company/dns/news/document/40388/content
👍️0
Golden Cross Golden Cross 4 years ago
KNBIF Website:

https://www.kanebiotech.com/
👍️0
Golden Cross Golden Cross 4 years ago
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (56 patents and patents pending, trade secrets and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. StrixNBTM, DispersinB®, Aledex®, bluestemTM, AloSeraTM, coactiv+TM and Kane® are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE".
👍️0
Golden Cross Golden Cross 4 years ago
Monster # of filings today $KNBIF

https://www.otcmarkets.com/stock/KNBIF/disclosure
👍️0
sfld sfld 4 years ago
This might pump this week. Mentioned in a National Inflation Association newsletter today. GLTA
👍️0
pegcitygreen pegcitygreen 5 years ago
I live in Winnipeg and have personally worked with this company. Great people, great products, but the company itself always seems to struggle. Kane products are for wealthy/well off people who love their pets and more than likely do not have any kids. A very, very niche market. Their tradeshows booth is quite impressive...but that doesn't mean impressive sales.
👍️0
teq0904 teq0904 5 years ago
CEO got 2M shares in the market now.
👍️0
teq0904 teq0904 5 years ago
Jan 30 cc and presentation shows the potential markets. Just sign into it and you end up with the archive. https://edge.media-server.com/m6/p/rzpqebyy
👍️0
Macaveli Macaveli 5 years ago
Decent news released today. Plus insiders are buying. This is a hidden gem.
👍️0
teq0904 teq0904 6 years ago
Sales are slow for this startup, however the products are superb so I imagine it will be a good company in the long run. I used the oral rinse and shampoo for my dog. I don't know if the rinse is the reason, but the vet told me this month that her teeth are in excellent shape for her age.
She also had a bad itch last winter and scratched day and night. It didn't stop with the use of a vet's prescription shampoo, so I tried the Kane product with excellent results. As soon as I put it on her she stops scratching for about 1 day, so I just apply it once daily wherever I see her scratching.

I know a guy who had terrible psoriasis itching on the scalp all day and night long but it all stopped when he used the human shampoo.
👍️0

Your Recent History

Delayed Upgrade Clock